BlossomHill To Present Updated SOLARA Data On BH-30643 In EGFR-Mutant Lung Cancer Today; Stock Up

BlossomHill Therapeutics (BLSM) will present updated results from its ongoing Phase 1/2 SOLARA trial of BH-30643, an investigational macrocyclic OMNI-EGFR inhibitor for EGFR-mutant non-small-cell lung cancer patients who developed secondary resistance. The article does not provide efficacy, safety, or financial results, limiting assessment of the trial update's investment significance.